id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-351517-npcuo1ld	Gale, Robert Peter	Liaisons Dangereuses? new drugs, physicians and the drug industry	2020-07-01		.txt	text/plain	2294	131	53	This is extraordinarily good news but raises questions whether everyone receiving a haematopoietic cell transplant needs and/or benefits from these new drugs and whether physicians were complicit in promoting their approval and subsequent use. For example, between 2009 and 2014 the US FDA-approved 83 cancer drugs, 55 based on surrogate outcomes including 31 based on overall response rate and 24 based on PFS [1] . Some data suggest one reason many new drugs gain favour with physicians and patients is because they are promoted by nationally or internationally by disease experts often referred to as key opinion leaders (KOLs) and by drug companies, often in media advertisements. Having invested several years studying a new drug, often with considerable effort and problems working with ethical committees, clinical research organizations (https://www.ashclinicalnews.org/viewpoints/ editors-corner/contract-research-agonizations/); sometimes known as clinical research aggravations), drug company study managers etc. However, the impact of many new approved drugs on transplant outcomes is mostly modest and not everyone needs them.	./cache/cord-351517-npcuo1ld.txt	./txt/cord-351517-npcuo1ld.txt